



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

May 19, 2020

R. Erik Holmlin, Ph.D.  
Chief Executive Officer  
Bionano Genomics, Inc  
9540 Towne Centre Drive, Suite 100  
San Diego, CA 92121

**Re: Bionano Genomics, Inc**  
**Preliminary Proxy Statement on Schedule 14A**  
**Filed May 13, 2020**  
**File No. 001-38613**

Dear Mr. Holmlin:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: James Pennington, Esq.